ÂÜÀòÂÒÂ×

Dr. Boado co-founded ArmaGen in 2004, following more than 25 years of academic experience in fields of molecular and cell biology of the BBB, and drug delivery to the brain. His leadership and expertise have been instrumental in the development of ArmaGen’s extensive product pipeline, including potential biotherapeutic treatments for mucopolysaccharidosis, stroke, Alzheimer’s disease and Parkinson’s disease. Dr. Boado was the principal investigator in a number of Small Business Innovation Research (SBIR) programs granted by the National Institutes of Health to ArmaGen. Dr. Boado is also a co-inventor of the intellectual property that supports ArmaGen’s pipeline. He was previously professor of Medicine at UCLA, and has published over 195 scientific peer-reviewed publications and book chapters related to the BBB. Dr. Boado received his Ph.D. in Biochemistry at the University of Buenos Aires.